by IMIM (Hospital del Mar Medical Research Institute) Credit: Pixabay/CC0 Public Domain The ICOD (Improving Condition in Down syndrome) project, a pioneering study in addressing the cognitive difficulties associated with Down syndrome, has demonstrated the safety of treatment with the molecule AEF0217, developed by the French biotech Aelis Farma, as well as its effectiveness in...
Tag: <span>down syndrome</span>
Post
Extra virgin olive oil may delay cognitive decline in Down syndrome
Researchers working with the Alzheimer’s Center at Temple (ACT) recently investigated the effect of extra virgin olive oil (EVOO) on brain health and memory to determine if consumption of extra virgin olive oil, the main component of the Mediterranean diet, can delay cognitive decline in people with Down syndrome (DS). DS is the most common...
Post
Clinical trial shows JAK inhibitor improves multiple autoimmune conditions in patients with Down syndrome
August 13, 2024 by CU Anschutz Medical Campus Acutal results of clinical trial participant with alopecia areata after four months of treament. Credit: Linda Crnic Institute for Down Syndrome Multi-organ autoimmunity and widespread autoantibody production in Down syndrome.A new study published in eLife by researchers from the Linda Crnic Institute for Down Syndrome (Crnic Institute)...
Post
Alzheimer’s Starts Earlier and Progresses Faster in People With Down Syndrome
A new study revealed that Alzheimer’s disease starts earlier and progresses faster in people with Down syndrome.Original story from Washington University School of Medicine in St Louis A scientist in a white lab coat helps a person with Down syndrome into a brain scan machine.Washington University senior clinical research coordinator Brittany Nelson (front) helps study...
Post
Weight loss may be early predictor of Alzheimer’s disease in those with Down syndrome
by Charlene N. Rivera-Bonet, University of Wisconsin-Madison Credit: Unsplash/CC0 Public Domain Unintentional weight loss in people with Down syndrome may predict the onset of Alzheimer’s disease long before typical cognitive symptoms like memory loss and dementia are apparent. As many as 90% of people with Down syndrome experience Alzheimer’s symptoms by the time they are...
Post
Down syndrome, like Alzheimer’s, is a double-prion disorder
by University of California, San Francisco PET scan of a human brain with Alzheimer’s disease. Credit: public domain The brains of people with Down syndrome develop the same neurodegenerative tangles and plaques associated with Alzheimer’s disease and frequently demonstrate signs of the neurodegenerative disorder in their forties or fifties. A new study from researchers at...
Post
A therapy found to improve cognitive function in patients with Down syndrome
by Institut National de la Sante et de la Recherche Medicale Credit: CC0 Public Domain An Inserm team at the Lille Neuroscience & Cognition laboratory (Inserm/Université de Lille, Lille University Hospital) has joined forces with its counterparts at Lausanne University Hospital (CHUV) to test the efficacy of GnRH injection therapy in order to improve the...
Post
Blood test detects Alzheimer’s in people with Down syndrome
by Lund University Credit: Unsplash/CC0 Public Domain Around 80% of people with Down syndrome develop Alzheimer’s disease, often when they are between 40 and 50 years old. A study led by Lund University in Sweden has shown that a simple blood test can detect Alzheimer’s disease in people with Down syndrome with a high degree...
Post
Earlier intervention in Down syndrome may be possible, study finds
by CU Anschutz Medical Campus Credit: Unsplash/CC0 Public Domain Could oxidative stress, a condition known to cause inflammation and cellular breakdown, impact the trajectory of Down syndrome cell development? Researchers at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences recently published findings that examine the early stages of neurodevelopment. What they found...
Post
Common antiretroviral drug improves cognition in mouse model of Down syndrome
by Center for Genomic Regulation Antiretroviral medication lamivudine pictured at the IrsiCaixa AIDS research institute in Barcelona. Credit: IrsiCaixa Lamivudine, a commonly-used antiretroviral drug for treating HIV, improves cognition in a mouse model of Down syndrome, according to the findings of a joint new study by researchers at the Centre for Genomic Regulation (CRG) and...
- 1
- 2